US IPO Lays Into EU Plans To Cut Data Protection & Extend ‘Bolar’ Exemption
Executive Summary
The IPO says some provisions in the EU pharma revision could contravene the TRIPS agreement, including plans to suspend regulatory data protection on products subject to a compulsory licence in times of health emergencies.
You may also be interested in...
EC Says ‘Bolar Exemption’ Should Cover Pricing, Reimbursement & HTA Processes
Pricing and reimbursement processes as well as health technology assessments should be explicitly included in the procedures that can be conducted for generic and biosimilar products without infringing patent rights, according to the European Commission’s legislative revision proposals.
EU Critical Medicines List To Be Ready ‘Within Days’
Members of the European Parliament were told that once the list was out, work would begin on identifying the products most vulnerable to supply chain problems.
Controversial EU Study On Pharma Innovation & Access Sees The Light Of Day
Members of the European Parliament committee charged with leading the negotiations on the review of the EU pharmaceutical legislation have been presented with a study backing cuts in data protection and wider joint procurement of medicines outside emergency situations.